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Abstract
Opsoclonus-myoclonus-ataxia syndrome is a heterogeneous constellation of symptoms ranging from full combination of 
these three neurological findings to varying degrees of isolated individual sign. Since the emergence of coronavirus disease 
2019 (COVID-19), neurological symptoms, syndromes, and complications associated with this multi-organ viral infection 
have been reported and the various aspects of neurological involvement are increasingly uncovered. As a neuro-inflammatory 
disorder, one would expect to observe opsoclonus-myoclonus syndrome after a prevalent viral infection in a pandemic scale, 
as it has been the case for many other neuro-inflammatory syndromes. We report seven cases of opsoclonus-myoclonus 
syndrome presumably parainfectious in nature and discuss their phenomenology, their possible pathophysiological relation-
ship to COVID-19, and diagnostic and treatment strategy in each case. Finally, we review the relevant data in the literature 
regarding the opsoclonus-myoclonus syndrome and possible similar cases associated with COVID-19 and its diagnostic 
importance for clinicians in various fields of medicine encountering COVID-19 patients and its complications.
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Introduction
Myoclonus is defined as brief, sudden, shock-like muscle 
contraction leading to jerky movements. It is further 
divided to positive and negative myoclonus based on 
increased activation or inhibition of muscle contraction. 
There are several classifications for myoclonus from 
different aspects; the most commonly used focuses on 
the generating site of myoclonus. This classifies the 
myoclonus as cortical, cortical-subcortical, subcortical/
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nonsegmental, segmental, and peripheral. Etiologic 
classification on the other side encompasses physiologic 
myoclonus, essential myoclonus, epileptic myoclonus, 
and symptomatic myoclonus (Caviness 2019). Opsoclonus 
as an ocular equivalent of myoclonus is irregular, 
arrhythmic, and chaotic eye movements in all directions 
of gaze which exacerbates with pursuit (Cameron and 
Kilbane 2019; Caviness 2019). It is in fact a saccadic 
disorder of eye movement also known as “saccadomania” 
and along with ocular flutter is categorized under the 
umbrella  term “saccadic intrusions without intersaccadic 
intervals”. Opsoclonus is more frequently accompanied 
by ataxia, encephalopathy, and myoclonus; accordingly, 
the term “opsoclonus–myoclonus syndrome” (OMS) was 
introduced (Lemos and Eggenberger 2013). Regarding 
the etiologic classification of myoclonus, OMS is placed 
under symptomatic myoclonus category and etiologically 
categorized into idiopathic, paraneoplastic, infectious, 
and other subgroups (Caviness 2019; Caviness and Brown 
2004).
Adult-onset OMS, unlike the similar disorder in 
children (referred to as Kinsbourne syndrome) is a 
less well-defined entity, especially in association with 
infections. The majority of reported cases in adults 
have been paraneoplastic in nature mostly in association 
with antineuronal nuclear antibody type 2 [ANNA-2; 
anti-Ri]. However many idiopathic cases with presumed 
parainfectious etiology seem to occur and these patients 
manifest a short duration (4–6 weeks) symptomatic phase 
and in most cases respond to immunotherapy (Klaas et al. 
2012). Symptoms, especially the myoclonus, alleviate with 
clonazepam or other drugs such as sodium valproate and 
levetiracetam (Kojovic et al. 2011).
As the new coronavirus infection disease (COVID-19) 
continues to be the major current health issue around the 
world, new symptoms regarding neurological aspect of this 
multi-system disease are being reported. Cerebrovascular 
disorders (e.g., ischemic stroke, intracerebral hemorrhage, 
cerebral vasculitis), altered mental status (due to 
encephalitis, encephalopathy, seizure, etc.), peripheral 
nervous system involvement (Guillain-Barré syndrome, 
myositis, etc.), and neuropsychiatric involvement (e.g., 
depression, personality change, catatonia, mania, and 
psychosis) have been the major neurological manifestations 
of COVID-19 frequently reported (Lu et  al. 2020; 
Varatharaj et  al. 2020). Regarding movement disorder 
neurological symptoms in COVID-19, the semiology, 
pathophysiology, and epidemiology of each movement 
disorder are still naïve. In some studies, there are 
classifications for staging the COVID-19 disease course. 
These stages have been proposed as acute respiratory 
distress syndrome, cytokine storm, acute hypercoagulable 
state, and autonomic dysfunction (Yamamoto et al. 2020). 
Although these may explain some of  the neurological 
aspects of COVID-19, we believe that there are much 
more aspects to focus on, phenomenologically and 
pathophysiologically, among them are parainfectious 
autoimmune syndromes. We have been consulted on seven 
cases with COVID-19 either in acute infectious phase or 
early after remission in whom the emergence of abnormal 
movements resembling OMS were noticeable.
Case report
We report here seven COVID-19 patients who developed 
similar symptoms, i.e., myoclonus. These cases were 
consulted with two of authors (MR and ME) in a referral 
center for movement disorders. The cases 1, 3, and 4 were 
reported from centers where two of the authors work and 
managed them (MB and MJ). Cases 2 and 5 were managed 
in the hospitals where two of the authors are practicing 
(MM and MZ, respectively). The 6th patient was referred 
for treatment to ME and MR. The 7th patient was recently 
managed by our colleague; FM, ME, and MR were consulted 
on this case. All patients gave their informed consent prior 
to their inclusion in the study. Patient’s characteristics and 
their disease-related information are summarized in Table 1.
Case 1. A 51-year-old male health-care staff (nurse) 
presented with sore throat, back pain, anorexia, and mild 
dyspnea. There was no leukocytosis, lymphopenia, or 
increment in erythrocyte sedimentation rate (ESR) or 
C-reactive protein (CRP). The chest CT revealed few 
peripheral patchy ground-glass opacities (Fig. 1). Brain 
CT was normal. His nasopharyngeal swab sample RT-PCR 
test result for COVID-19 was positive. He was treated with 
non-steroidal anti-inflammatory drugs (piroxicam IM) 
for myalgia, hydroxychloroquin, and azithromycin. Two 
weeks after initial symptoms, he noticed tremor-like jerky 
movements in his hands which progressively increased in 
severity and became worse with intentional movements. 
After several days, his legs and voice were involved with 
tremor and he noticed oscillopsia. His jerky movements 
diagnosed as generalized stimulus sensitive and action 
myoclonus, treated with clonazepam 0.5  mg qhs and 
levetiracetam 500 mg bid. His extra ocular movements 
were fragmented during pursuit movements intermixed 
with jerky oscillatory movements of eyes in all directions 
(opsoclonus) and corrective rapid head movements. There 
was slightly truncal ataxia (wide-based gait) more prominent 
during tandem walking (Online Resource 1). Based on these 
symptoms, parainfectious OMS was presumed and IVIG was 
started to a total dose of 150 g (2 g/kg). The improvement of 
abnormal movements was noticeable after 1 week of IVIG 
initiation and markedly improved 3 weeks after treatment 
(Online Resource 2–4). Clonazepam and levetiracetam 
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4 weeks after treatment were discontinued and there were 
no abnormal movement’s thereafter.
Case 2. A 54-year-old man was admitted to the hospital 
with dyspnea. His symptoms started with malaise, fever, 
myalgia, coughs, and 2 days later dyspnea. After nearly 4 
days of symptoms’ onset, he developed generalized jerky 
movements. His voice and ocular movements were spared. 
Examination revealed generalized myoclonic jerks exac- 
erbating with intentional movements and sudden noises 
(Online Resource 5). Chest CT showed patchy peripheral 
ground glass opacities and consolidations in both lungs, 
much more severe than case 1 (Fig. 2). Brain MRI was nor- 
mal. Blood count revealed leukocytosis (WBC = 11,500) but 
lymphocyte count was 2300. ESR was 45 mm/h and CRP 
was highly positive (2+). Serum electrolytes were within 
normal limits. CSF analysis for cell count, protein, and glu- 
cose was normal. Nasopharyngeal and CSF RT-PCR test 
for COVID-19 were negative but serologic survey for both 
IgG and IgM in serum were positive. Treatment with leveti- 
racetam (2000 mg/day), sodium valproate (1000 mg/day), 
and IVIg (100 g total) after 5 days resulted in  significant 
resolution of myoclonic movements and he was discharged 
with levetiracetam and sodium valproate planned to be 
tapered within 1 month.
Case 3. This 52-year-old man with history of chronic 
lung disease came to hospital initially with dry cough, 
low grade fever, and headaches started 1 week earlier. His 
laboratory tests revealed WBC = 6600/µL, lymph = 1700/µL, 
ESR = 30 mm/h, and CRP = 2+ and normal serum electrolytes. 
Chest CT showed typical COVID-19 involvements (Fig. 3). 
Nasopharyngeal swab RT-PCR test was positive for COVID-
19. Treatment for respiratory disease started with oseltamivir, 
lopinavir/ritonavir, hydroxychloroquine (hospital protocol at 
that time), and he was discharged after 4 days. Sixteen days 
after initial symptoms, he developed generalized stimulus 
(somatosensory and auditory) sensitive myoclonus, involving 
his voice as well, but not eye movements. His movements 
became severe and disabling after 3 days making him unable 
to walk. He was admitted again. Brain MRI was normal. 
Sodium valproate 1000 mg/day and clonazepam 1 mg qhs 
were beneficial, enabling him to walk with help. Chest CT was 
in favor of superimposed bacterial pneumonia and treatment 
with IV antibiotics started. He declined immunotherapy and 
was discharged with oral levofloxacin, sodium valproate, 
and clonazepam. He did not consent for taking his video but 
allowed anonymous data consumption for this paper. After 
2-month follow-up, his movements were still present but 
trivial and he was still on medications.
Case 4. A 42-year-old lady visited our clinic, 10 days 
after initial diagnosis of COVID-19 with initial symptoms 
of fever, myalgia and coughs, developed jerky movements 
of hands and feet (more severe on right side), voice tremor, 
imbalance, and gait disturbance. On neurological examina-
tion, she had generalized myoclonus, dysarthria, and mild 
truncal ataxia similar to case 1 (but less severe). There was no 
prominent ocular movement involvement. Other neurological 
examinations were intact. Clonazepam and sodium valproate 
were started for abnormal movements. Unfortunately, we lost 
the follow-up of this patient, but we think her symptoms got 
improved since her respiratory and movement disorders were 
mild and none of our colleagues in the local area which is a 
small city have visited her since then.
Case 5. The other similar patient about whom we were 
consulted was a 44-year-old gentleman, presented with 
fever, chills, and 3 days later one episode of generalized 
tonic-clonic seizure. The same day, he developed opso-
clonus, generalized stimulus sensitive and action myoclonus 
and ataxia, which after several days made him completely 
disabled and unable to sit or walk. His voice was tremulous 
as well (Online Resource 6–9). Chest CT was in favor of 
COVID-19 diagnosis (Fig. 4). Brain MRI, EEG, and CSF 
analysis were normal. Treatment with intravenous ceftri-
axone, oral azithromycin, and anti-viral drugs Daclatasvir/
sofosbuvir (Sovodak®) was instituted. With the presumed 
diagnosis of OMS, we started sodium valproate, clonaz-
epam, and IVIG. After 1 week, with partial resolution 
Fig. 1  Chest computed tomography (CT) scan of case 1 shows few peripheral patchy ground-glass opacities in both lungs
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of symptoms, he was discharged (see Online Resource 
6–9). Follow-up at 2  months showed no abnormal 
movements.
Case 6. Fifty-two-year-old male nearly 1 month after 
initial symptoms of fever, myalgia, and cough was referred 
to us for treatment of abnormal movements. Neurological 
examination revealed generalized myoclonus with intentional 
component, mild ataxia, and severe shuffling gait. Voice 
involvement was prominent but there was no opsoclonus 
(Online Resource 10). Chest CT scan (Fig. 5) was in favor 
of COVID-19 diagnosis and nasopharyngeal swab RT-PCR 
test confirmed the diagnosis. CSF protein, glucose, and cell 
count were normal and PCR for common viral and bacterial 
pathogens as well as COVID-19 in CSF was negative. Serum 
and CSF panel for autoimmune encephalitis antibodies were 
negative. No oligoclonal band was detected. Treatment with 
clonazepam and IVIG (100 g total) resulted in significant 
improvement after 4 weeks (Online Resource 11).
Case 7. This very recent patient of us, a 39-year-old man, 
presented with fever, cough, myalgia, nausea, vomiting, and 
10 days later, one episode of generalized tonic-clonic seizure. 
The same day, he began to suffer from jerky movements. 
Examination revealed prominent opsoclonus, generalized 
Fig. 2  Chest CT scan of case 2 shows patchy peripheral ground glass opacities and consolidations in both lungs
Fig. 3  Chest CT scan of case 3 shows patchy peripheral ground glass opacities and consolidations in both lungs typical for COVID-19 involvements
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myoclonus with intentional component, and ataxia. His voice 
was severely involved (Online Resource 12). Chest CT was 
diagnostic for COVID-19 (Fig. 6). Brain CT was normal. 
Abnormal laboratory tests included AST = 61 U/L, ALT = 69 
U/L, ESR = 58 mm/h, CRP = 75.4 mg/L. He was started on 
levetiracetam, clonazepam, IVIG, and dexamethasone. After 
2 days, sudden increase in serum creatinine (Cr = 5) made us 
to stop IVIG and change levetiracetam to sodium valproate. 
He is still under treatment for severe respiratory involvement 
and acute renal failure. Clonazepam and sodium valproate 
alleviated myoclonus but improvement in general condition 
and OMS merits long-term follow-up.
Discussion
Opsoclonus-myoclonus-ataxia syndrome is a heterogeneous 
constellation of symptoms ranging from full combination 
of these three neurological findings to varying degrees of 
isolated each individual sign. In a review of patients with 
adult-onset OMS, one third had flu-like symptoms before 
the emergence of abnormal movements and 40% revealed 
either elevated IgG index or oligoclonal bands, none of 
them being paraneoplastic in follow-up, but results for 
presumed infections to establish parainfectious source were 
negative. Eighty percent received immunotherapy (IVIG, 
Fig. 4  Chest CT scan of case 5 shows patchy peripheral opacities (circles) in both lungs more severe in right lung in favor of COVID-19 diagnosis
Fig. 5  Chest CT scan of case 6 shows patchy peripheral opacities in both lungs in favor of COVID-19 diagnosis
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corticosteroids, plasma exchange, or a combination of them) 
and almost all of non-paraneoplastic cases improved. Proven 
infection was identified in 13% of OMS patients extracted 
from review of the literature (Klaas et al. 2012).
Since the emergence of COVID-19, neurological 
symptoms, syndromes, and complications associated 
with this multi-organ viral infection have been reported 
and the various aspects of neurological involvement are 
increasingly uncovered. There have been a proposed 
staging for COVID-19 defined as acute respiratory 
distress syndrome, cytokine storm, acute hypercoagulable 
state, and autonomic dysfunction (Yamamoto et  al. 
2020), but this may explain some aspects of neurological 
COVID-19.  Many para infec t ious  au to immune 
complications such as Guillain-Barré syndrome are 
increasingly reported (Varatharaj et  al. 2020) and 
these immune-mediated complications may occur with 
varying interval from initial COVID-19 symptoms and 
may overlap with each of the above mentioned stages. 
As a neuro-inflammatory disorder in nature, one would 
expect to observe OMS after a prevalent viral infection in 
a pandemic scale, as it has been the case for many other 
neuro-inflammatory syndromes (Paterson et al. 2020).
However, the syndrome as a specific consideration related 
to COVID-19 has not been discussed fully in the literature. 
Here, we presented seven similar OMS cases after COVID-
19, which we were consulted for, as a movement disorder 
referral center.
The best similar report regarding this disorder, has been 
in three patients, xwith generalized myoclonus following 
the inflammatory phase of COVID-19. None of them had 
opsoclonus, all three had encephalopathy and responded to 
immunotherapy indicating a parainfectious immune mecha- 
nism (Rábano-Suárez et al. 2020).
Myoclonus as a component of COVID-19-associated 
delirium has been reported by others and presumed to be a 
feature of generalized brain dysfunction in encephalopathic 
patients (Beach et al. 2020). Others also reported COVID-19-
associated encephalopathy having myoclonus in their clinical 
picture and assumed brainstem involvement as the pathogenic 
mechanism (Chaumont et al. 2020). There is a case report 
of clozapine toxicity in a COVID-19 patient who also had 
myoclonus (Cranshaw and Harikumar 2020). Also, there is 
report of a patient in UK-wide surveillance study with OMS 
but we were not able to access data regarding encephalopathy 
in this case (Varatharaj et al. 2020). Same authors reported a 
patient with OMS who had been encephalopathic and assumed 
to have autoimmune encephalitis with brainstem involvement 
(Paterson et al. 2020). There is a recent report of a COVID-19 
patient who developed generalized action myoclonus 1 month 
after respiratory disease and the authors presumed it to be 
post-hypoxic in nature, although there was no solid evidence 
for this etiology in our view (Ros-Castelló et  al. 2020). 
Another similar patient with generalized action myoclonus 
and ataxia (with voice involvement but without opsoclonus) 
occurring 2 weeks after severe respiratory disease, has been 
reported (Dijkstra et al. 2020). The latter is very similar to 
our cases except for the fact that it has been following severe 
COVID-19 respiratory phase but six out of seven cases, we 
reported here, have been after a mild to moderate respiratory 
disease according to Wu and McGoogan definition (Wu and 
McGoogan 2020). Their patient had been more responsive 
Fig. 6  Chest CT scan of case 7 shows patchy predominantly peripheral ground glass opacities and consolidations in both lungs supporting the 
COVID-19 diagnosis
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to IVIG than high-dose methylprednisolone pulse therapy,in 
accordance to our experience.
It seems that the OMS merits more attention as an 
independent immune parainfectious syndrome, with possible 
relationship to COVID-19 as the initial trigger infection. 
The interesting point in our patients was the absence of 
encephalopathy and variable interval after respiratory 
disorder, which was very mild in the first patient. This may 
indicate a syndrome independent of encephalopathy or direct 
effect of infection. The dramatic effect of immunotherapy 
on recovery in cases 1, 5, and 6 in comparison with case 
3 confirms the immune-mediated mechanism for this 
myoclonic syndrome. We believe some of the reported 
patients in the literature may have been suffering from the 
same immune OMS syndrome, which was overlapped by the 
respiratory or encephalopathic phase of COVID-19. This 
alarms the possibility of under-diagnosing an autoimmune 
encephalitic process, if untreated, it may further complicate 
the overall outcome of COVID-19 patients. Awareness of 
the possibility of such disorder and becoming familiar with 
its features,  which are easy to recognize even in critical 
settings, might help in better diagnosis and correctly 
choosing the COVID-19 patients that may benefit from 
immunotherapy.
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